Intensive blood pressure treatment was associated with a higher risk of probable dementia among participants who developed new-onset orthostatic hypotension (HR 2.39; 95% CI 1.33-4.32).
RCT (n=7,911)
randomised
Does intensive blood pressure treatment affect the risk of probable dementia in patients who develop new-onset orthostatic hypotension?
Intensive blood pressure lowering to <120 mmHg may increase the risk of probable dementia in patients who develop new-onset orthostatic hypotension during treatment.
Hazard Ratio: 2.39 (95% CI 1.33–4.32)
Abstract Background Orthostatic hypotension (OH) increases the risk of dementia. Although intensive blood pressure (BP) lowering may have cognitive benefits regardless of baseline OH status, its effects in participants who develop OH during intervention remain unknown. Methods Participants of the Systolic Blood Pressure Intervention Trial (SPRINT) were randomised to either intensive treatment (systolic BP target 120 mmHg) or standard treatment (systolic BP target 140 mmHg). This post hoc analysis defined new-onset OH as a systolic BP reduction ≥20 mmHg and/or a diastolic BP reduction ≥10 mmHg from a seated to a standing position at any follow-up visit during intervention. The primary outcome was probable dementia. Other outcomes included mild cognitive impairment (MCI), and a composite of probable dementia or MCI. Results Amongst 7911 participants without OH at baseline (representing 84.5% of randomised participants in SPRINT; mean age, 67.7 years; 34.7% women), 1264 (16.0%) developed new-onset OH during intervention. Intensive treatment was associated with a lower risk of probable dementia (HR, 0.76; 95% CI, 0.58 to 0.98) amongst participants without new-onset OH, but with a higher risk (HR, 2.39; 95% CI, 1.33 to 4.32) amongst participants with new-onset OH. No significant association was observed between intensive treatment and MCI, or the composite outcome in participants with new-onset OH. Conclusions The occurrence of OH requires close monitoring, with caution for potential cognitive adverse effects during ongoing intensive BP-lowering treatment. Validation of current findings in studies with justified methodological designs is warranted. Registration URL: ClinicalTrials.gov; Unique Identifier: NCT01206062.
Wang et al. (Thu,) conducted a rct in Hypertension without baseline orthostatic hypotension (n=7,911). Intensive blood pressure treatment vs. Standard treatment (systolic BP target <140 mmHg) was evaluated on Probable dementia (HR 2.39, 95% CI 1.33 to 4.32). Intensive blood pressure treatment was associated with a higher risk of probable dementia among participants who developed new-onset orthostatic hypotension (HR 2.39; 95% CI 1.33-4.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: